PREMIER BIOMEDICAL, INC. (OTCMKTS:BIEI) Files An 8-K Unregistered Sales of Equity Securities


PREMIER BIOMEDICAL, INC. (OTCMKTS:BIEI) Files An 8-K Unregistered Sales of Equity Securities

Item 3.02 Unregistered Sales of Equity Securities.

On August 19, 2016, two of our officers and directors, William A.
Hartman and Mitchell Felder, exercised warrants to acquire four
million (4,000,000) shares of common stock each. The aggregate
consideration for the warrants was $40 each ($0.00001 per share).
The issuance was exempt from registration to Section 4(a)(2) of
the Securities Act of 1933, the investors are accredited and
familiar with our operations and there was no solicitation in
connection with the issuance.

Section 9 Financial Statements and Exhibits.



Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for humans, specifically focusing the treatment of Cancer, Multiple Sclerosis (MS), Neuropathic Pain, Amyotrophic Lateral Sclerosis (ALS/Lou Gehrig’s Disease), Fibromyalgia, Traumatic Brain Injury (TBI), Alzheimer’s disease (AD), and Blood Sepsis and Viremia. The Company intends to develop its Sequential-Dialysis Technique, to target Cancer, Alzheimer’s disease, ALS, Blood Sepsis, Leukemia and other life-threatening cancers. The Sequential-Dialysis Technique is a methodology for the removal of those molecules, which are harmful and responsible for causing diseases. Its Sequential-Dialysis Technique method removes those excitatory neural transmitters that cause the death of those cells. It also intends to develop Feldetrex, a candidate drug, for the treatment of MS, Fibromyalgia and TBI. Feldetrex utilizes a low dosage of Naltrexone to increase endogenous enkephalins10.


PREMIER BIOMEDICAL, INC. (OTCMKTS:BIEI) closed its last trading session 00.00000 at 0.00430 with shares trading hands.